Stock FLHLF FILAMENT HEALTH CORP.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Filament Health Corp.

Equities

FLHLF

CA31685W1068

Market Closed - OTC Markets
Other stock markets
 14:47:13 25/06/2024 BST 		5-day change 1st Jan Change
0.0335 USD +0.15% Intraday chart for Filament Health Corp. +11.67% -38.08%
06-12 Filament Health Corp. announced that it has received CAD 1 million in funding from Negev Capital CI
06-03 Filament Health Announces Authorization of Phase 2 Clinical Trial for PEX010 in the Treatment of Methamphetamine Use Disorder CI

Other languages

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Filament Health Announces Authorization of Phase 2 Clinical Trial for PEX010 in the Treatment of Methamphetamine Use Disorder
Filament Health Corp. Reports Earnings Results for the First Quarter Ended March 31, 2024
Filament Health Corp. Announces Change to Board of Directors
Filament Health Corp. Reports Earnings Results for the Full Year Ended December 31, 2023
Filament Health Corp. Announces Appointment of Michael Messinger to Its Board of Directors and Chair of the Audit Committee
Filament Health Corp. Announces Shipments of Botanical Psilocybin to Four Countries for Clinical Investigation
Filament Health Corp. Completes the First Export of Botanical Psilocybin to Israel
Filament Health Announces FDA Opening of Investigational New Drug Application for Substance Use Disorders
Filament Health Completes the First Export of Biological Psilocybin to Australia
Filament Health Announces Change to Board of Directors
Filament Health Corp. (OTCPK:FLHL.F) cancelled the acquisition of Jupiter Acquisition Corporation from a group of shareholders in a reverse merger transaction.
Filament Health Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Filament Health Announces Health Canada Authorization for Phase 2 Clinical Trial Studying Botanical Psilocybin for Opioid Use Disorder
Filament Health Corp. Enters Licensing Agreement with Reset Pharmaceuticals Inc
Filament Health Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
Filament Health Corp. Announces FDA Approval of Two Clinical Trials Studying Its Biological Psychedelic Drug Candidate PEX010
Filament Health Corp. to Supply Psilocybin for Two Clinical Trials
Filament Health Corp. Enters Exclusive Licensing Agreement with NeoLumina Bioscience Inc
Filament Health Corp. Announces Interim Results from Phase I Clinical Trial at the University of California, San Francisco
Filament Health Corp. Reports Earnings Results for the First Quarter Ended March 31, 2023
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. FLHLF Stock
  4. News Filament Health Corp.
  5. Other languages